Amethyst Radiation Oncology Expert Featured On Zena Platform

/in

Dr David Kuczer, radiation oncology expert with Amethyst Group, has been interviewed by leading Serbian news platform Zena, talking about the role that radiotherapy has to play in breast cancer treatments.

Speaking to the news source, Dr Kuczer explained that all treatments are individually designed to suit each specific patient, using the most innovative and up-to-date knowledge to deliver optimal results, medically and aesthetically.

The interdisciplinary team at Amethyst’s Department of Tumours works collaboratively to come up with uniquely tailored approaches to patient care. From Dr Kuczer’s perspective, he believes it’s most important to spend time with patients while working on idea exchanges with colleagues and finding the best treatment options on a case by case basis.

He said: “Thanks to modern technology, the therapy has been reduced from about 30 treatments during six weeks to five to 20 treatments over the course of one to four weeks, depending on the individual case. The sessions last ten minutes and are performed on an outpatient basis.”

Around 50 per cent of all breast cancer patients will have to have radiotherapy, with high doses of radiation directed towards tumours to damage diseased cell DNA sufficiently to prevent multiplication. Once the tumour cells die, they’re broken down by the body.

This way of working means that tissue affected by the tumour can be removed, protecting the entirety of the breast and removing the need for complete removal. Recurrence is also prevented through the elimination of microscopic tumour remnants.

Finding innovative ways of treating cancer is a must, given that the disease is the leading cause of death around the world, with nearly ten million fatalities each year.

Here at Amethyst Group, we work tirelessly to identify new treatment methods to kill and eliminate malignant cells while preserving healthy tissue. To find out more, get in touch with the team today.

Serbian News Portal Features Amethyst Austria

/in

BLIC, one of the leading news portals in Serbia, has just published an article on its platform showcasing cancer care provider Amethyst Austria and its successes in fighting cancer using innovative radiotherapy treatments and techniques.

The article features Dr Alinca Sturdza, radiation oncology expert and gynecology expert, who trained in her specialism at Princess Margaret University Hospital in Toronto.

Dr Sturdza said: “As an expert in brachytherapy, one of the most precise forms of cancer treatment with radiation, I use the most modern methods of radiotherapy. Thanks to the constant advances in oncology, cancer is becoming a chronic disease in many cases and I’m here to support patients on that journey as best as possible.”

The radiotherapy centre itself can be found in the heart of Vienna, enjoying close relationships with a team of international cancer experts to help people from all over the world receive the highest standards of care possible through the provision of the most advanced form of cancer therapy.

Also featured in the BLIC news piece was radiation oncology specialist Dr David Kuczer, who has over 20 years of experience in radiation therapy, treating cancerous lesions including breast and prostate cancer.

At the Austria clinic, radiotherapy techniques have been developed to make sure that optimal radiation doses are targeted towards tumours, ensuring that minimal damage is done to surrounding health tissue.

Over the years, we have built up an established network of clinics and work closely with experienced partners to deliver highly coordinated specialist teams for cancer treatment. As such, patients can expect to receive expert care and optimal treatment, inline with international and national guidelines.

To find out more about the different therapy options available and how they could help support you in your cancer journey, get in touch with the Amethyst Austria team today.

Amethyst Healthcare Acquired by Fremman

Amethyst Healthcare Group Enters Growth Chapter with Acquisition by Fremman Capital

/in

Amethyst Radiotherapy Group (“Amethyst”), a leading pan-European provider of cancer care services, today announced that it has entered into an agreement to be acquired by Fremman Capital, a pan-European mid-market private equity firm. This strategic partnership marks a significant milestone in Amethyst’s journey and sets the stage for accelerated expansion and innovation across the European oncology landscape.

Founded in 2010, Amethyst has become one of the largest independent radiotherapy providers in Europe. Operating 19 cutting-edge cancer treatment centers across France, Poland, Romania, the UK, Italy, and Austria, Amethyst treats more than 50,000 patients annually. The Group delivers a comprehensive suite of oncology services — primarily radiotherapy — through a dedicated team of over 500 healthcare professionals and in collaboration with nearly 100 partner physicians.

As part of the transaction, Fremman Capital will acquire a majority stake in Amethyst, while the company’s founding shareholders and The Rohatyn Group will fully exit their investment. Fremman brings deep experience in healthcare and a strong track record of scaling essential service providers across Europe, making them a natural partner to support Amethyst’s long-term vision.

This partnership with Fremman marks a new era of opportunity for Amethyst,” said Stéphane Carré, CEO of Amethyst Radiotherapy Group.

“Their expertise in healthcare and long-term investment philosophy aligns perfectly with our mission: to deliver advanced, accessible cancer care to more people, in more places. With their support, we will continue investing in cutting-edge technologies, expanding our footprint both organically and through partnerships and M&A, making a difference in the lives of patients and families across Europe.”

 

Amethyst has built a strong reputation for clinical excellence, operating nearly 40 state-of-the-art linear accelerators — the primary technology used in modern radiotherapy — and forming long-standing partnerships with public health systems to ensure the equitable delivery of life-saving care.

The radiotherapy market continues to show strong growth, driven by rising cancer incidence and increasing recognition of radiotherapy as a highly effective, non-invasive treatment option with minimal side effects. Fremman’s investment underscores the strength of Amethyst’s model and its leadership position in this critical area of cancer care.

The transaction is expected to close in the coming months, subject to customary regulatory approvals.

 

About Amethyst Radiotherapy
Amethyst is a leading European cancer care provider specialising in radiotherapy, chemotherapy, and diagnostic imaging. With operations in six countries and 19 centers, Amethyst combines clinical excellence with patient-centered care to improve access to oncology treatment across Europe. The Group partners closely with public healthcare systems, delivering services under reimbursement-based models.

About Fremman

Fremman Capital is a pan-European, mid-market investment firm with offices in London, Luxembourg, Paris, Madrid, and Munich. The firm partners with ambitious management teams to help transform businesses into multinational sustainable leaders, particularly in sectors essential to society such as healthcare, technology, and business services.

For more information: www.fremman.com

Media Contact:
Sophie Ward
Email Address: [email protected]
Phone Number: +44 208 713 0460
Organisation Website: www.amethysthealthcare.com

Inside Amethyst Healthcare’s PPP Strategy with CEO Stephane Carre

/in

In today’s rapidly evolving healthcare landscape, Public–Private Partnerships (PPPs) represent more than just a financial model—they serve as a cornerstone for innovation, increased access, and long-term sustainability. Amethyst Healthcare Group, under the leadership of CEO Stéphane Carré, is championing this approach. In a recent interview with The CEO Magazine, Carré detailed how Amethyst is strategically leveraging PPPs to deliver cutting-edge cancer care to more patients across Europe.

The Role of PPPs in Modern Healthcare

Healthcare systems across Europe are grappling with a dual pressure: tightening budgets and rising demand for services. PPPs present a viable solution by combining the reach and reliability of public institutions with the agility and technological edge of private enterprise. When executed effectively, these partnerships can enhance service quality, increase efficiency, and broaden patient access.

Amethyst has been a firm advocate of this collaborative model since its inception. Through enduring partnerships with hospitals and public health organizations, the company provides advanced radiotherapy services—relieving pressure on public resources while ensuring high standards of patient care. This alignment results in a dual benefit: enhanced healthcare delivery for patients and sustainable models for providers.

Expanding Access Through Real-World Impact

One notable example of Amethyst’s PPP success is its collaboration with Centre Hospitalier de Troyes in France. By managing the hospital’s radiotherapy unit, Amethyst enables the facility to offer cutting-edge treatments without requiring a substantial capital outlay. This approach removes financial and operational barriers, significantly improving access to lifesaving care—especially in underserved regions.

In the UK, the company’s acquisition of Queen Square Radiosurgery Centre in London brought advanced Gamma Knife technology to both private and NHS patients. Since 2023, patient numbers at the center have doubled, underscoring how PPPs can rapidly enhance treatment capacity and introduce breakthrough technologies into public healthcare frameworks.

Driving Innovation While Sharing Risk

One of the key advantages of PPPs is the ability to introduce innovation without placing the entire financial or operational burden on public systems. Amethyst’s model epitomizes this principle. By investing in and managing radiotherapy centers on behalf of public institutions, the Group delivers excellence in care with a streamlined, patient-focused approach.

This model not only facilitates faster adoption of advanced technology but also enhances overall service quality—reducing waiting times, minimizing inefficiencies, and improving patient outcomes.

Scaling for Sustainable Impact

Since 2020, Amethyst has recorded an 84% increase in the number of patients treated annually, including a 70.1% rise in NHS-referred patients. These figures highlight more than just growth—they reflect the potential of PPPs to sustainably expand healthcare capacity and ease the burden on national systems like the NHS.

Looking ahead, Amethyst plans to scale its operations to 50 clinics and over 100 linear accelerators across Europe. This ambitious expansion is firmly anchored in its PPP-driven strategy, which remains a central pillar of the Group’s vision for the future.

Redefining Collaborative Healthcare

For Amethyst, PPPs are not merely funding mechanisms—they are strategic enablers. By aligning the capabilities of the private sector with the needs of the public, these partnerships create resilient systems that can grow, adapt, and consistently deliver high-quality care.

As Stéphane Carré noted in his interview with The CEO Magazine, the future of healthcare lies in intelligent collaboration. PPPs will continue to play a transformative role—not just in oncology, but across all sectors of healthcare seeking scalable, impactful, and sustainable solutions. Amethyst Healthcare is proud to be leading this transformation.

Read the full interview with Stéphane Carré in The CEO Magazine for more insights into Amethyst Healthcare Group’s inspiring journey.
Radiotherapy Treatment - MRI Scan

What’s Next For Gamma Knife Radiosurgery & AI Technology?

/in , ,

One of the most effective and advanced treatment resources for brain tumours and vascular malformations is Gamma Knife radiosurgery, which first came to the fore during the 1960s and which has continued to evolve quickly ever since.

With the advent of artificial intelligence (AI) over the last year or so, new and exciting opportunities are starting to emerge… some of which have just been published in the spring edition of SCOPE magazine, with contributions from our own clinical team, including Ian Paddick (consultant physicist at Queen Square) and Hannah Bouas (radiosurgery physicist at Thornbury Radiosurgery Centre).

The focus here is on AI-driven auto-contouring for tumour segmentation, achieving greater levels of precision and more consistent patient outcomes in stereotactic radiosurgery.

Read on to find out more about the key conclusions drawn in the Scope piece.

AI-driven auto-contouring for advanced precision

AI-driven auto-contouring for tumour segmentation is a significant breakthrough in Gamma Knife technology, moving away from manual processes that are time consuming and subject to risks posed by human interpretation, particularly in lesions and tumours that don’t have clearly defined boundaries.

Using AI frameworks allow clinicians to segment tumour boundaries with the equivalent accuracy to human annotators, the advantages of which include:

– Reduced human error: Consistency is achieved through AI automation, lowering the risk of inaccurate results while reducing variability and oversights significantly.

– Enhanced patient outcomes: AI tools ensure greater accuracy of tumour segmentation, resulting in more precise radiation delivery to tumour cells and reducing damage risks to healthy brain tissue, as well as reducing the risks of complications and side-effects.

– Efficiency gains: Automation allows for more efficient contour detection in much shorter timescales, thus allowing for faster overall treatment times and reduced waiting lists.

Potential limitations of AI

Although the Scope article does note that AI is an incredibly valuable tool, models for auto-contouring still have some limitations, such as incomplete training data that may not generalise across diverse populations, or imaging noise that results in false positives.

While AI will undoubtedly become more important as a resource in the future, for now clinical oversight and judgement of contouring processes will still be necessary, particularly for more complex cases such as brain metastases.

Amethyst France Partners with CROMG to Improve Cancer Care

/in

Amethyst Radiotherapy France is proud to announce a strategic partnership with the Centre Radiothérapie Oncologie Moyenne Garonne (CROMG), a renowned radiotherapy centre based in Agen. This new collaboration marks a significant step forward in advancing oncology care in the South of France, uniting two organisations committed to delivering exceptional radiotherapy services through innovation, expertise, and compassion.

Founded in 2008, CROMG has long been recognised as a leader in the region, equipped with three state-of-the-art linear accelerators (Linacs) and a highly experienced medical team. Through this partnership, Amethyst aims to reinforce CROMG’s legacy while introducing enhanced clinical pathways, advanced technologies, and broader access to patient-centric treatment closer to home.

“This partnership reflects our shared vision to provide world-class radiotherapy services and ensure patients across the Nouvelle-Aquitaine region have access to the latest in cancer treatment,” said Olivier Cosset, Amethyst France CEO. “We are excited to welcome the CROMG team into the Amethyst family and support the continued growth of their outstanding medical expertise.”

By integrating resources, teams, and know-how, Amethyst and CROMG will work together to maintain the highest standards of care while expanding access and strengthening local oncology networks. The partnership will also foster the development of multidisciplinary approaches, supporting not only radiotherapy but broader oncology collaboration across the region.

This collaboration marks an exciting milestone in Amethyst’s continued expansion in France, reinforcing its mission to make high-quality, innovative radiotherapy accessible to more patients, wherever they are.

About Amethyst Radiotherapy
Amethyst Radiotherapy is one of Europe’s leading private cancer treatment providers, delivering high-precision radiotherapy services through a network of state-of-the-art centres. With a strong presence in France and across Europe, Amethyst is dedicated to innovation, medical excellence, and improving patient outcomes.

About CROMG
The Centre Radiothérapie Oncologie Moyenne Garonne (CROMG) has been at the heart of cancer care in Agen since 2008. Committed to personalised treatment and cutting-edge radiotherapy, the centre is home to an expert medical team, serving patients across the Nouvelle-Aquitaine region with compassion and excellence.

Media Contact:
Sophie Ward
Email Address: [email protected]
Phone Number: +44 208 713 0460
Organisation Website: www.amethysthealthcare.com

Amethyst Radiotherapy France Featured on Check-Up Santé

/in , ,

Acclaimed French television show Check-Up Santé on BFM TV , which focuses on health information and regularly invites medical experts onto the stage to discuss important topics of the day, has asked Olivier Cosset, CEO of Amethyst Radiothérapie France, to appear as a guest on Saturday, 22nd February and Sunday 23rd February.

Mr Cossett will be on the BFM TV flagship health programme talking in depth about the latest innovations in radiotherapy and the increasingly important role the practice has to play in modern cancer treatment, delivering insights into how it is evolving to make cancer treatment more effective and accessible.

“Radiotherapy is undergoing a true revolution, with advancements that are making treatments more precise, efficient, and accessible to more patients than ever before. At Amethyst Radiothérapie France, we are committed to bringing the latest innovations in radiotherapy to improve patient care and outcomes. I look forward to discussing these exciting developments on Check-Up Santé with Fabien Guez and shedding light on how radiotherapy is shaping the future of cancer treatment.”

– Olivier Cosset, CEO of Amethyst Radiothérapie France

Amethyst Radiothépie is one of the biggest private providers of radiotherapy services in France, providing cutting-edge treatments to enhance the patient journey and improve health outcomes across the board.

The episode is due to air on 22nd February at 14:00 EST and Sunday 23rd February at 15:00 EST on BFM TV. Make sure you tune in to hear a truly fascinating discussion on radiotherapy innovation and what the future of cancer care will look like.

Also featuring on the show will be Professor Jean-Emmanuel Bibault, who will be talking about the long history of cancer (which dates all the way back to prehistoric times), just one of the points raised in his book Cancer Confidential: L’histoire du cancer, des secrets d’hier aux revolutions de demain.

The Die Presse Front Page

Amethyst Radiotherapy Featured By Die Presse

/in ,

We are pleased to share that Amethyst Radiotherapy Austria has been featured on the front page of Die Presse, one of Austria’s leading broadsheet newspapers. This recognition highlights our Vienna-based centre’s excellence in delivering advanced radiotherapy services.

This feature underscores the dedication and expertise of our team in providing innovative treatments for complex conditions, particularly cancer—one of the world’s leading causes of mortality.

In the article, Centre Director Paul Stuchetz discusses our commitment to helping patients achieve the best possible outcomes through cutting-edge therapies, with integrative cancer treatment at the core of our approach.

Readers will also find insights into radiation therapy as a treatment option, including the benefits of external beam radiation in managing various cancers. The article highlights prostate cancer, an aggressive disease that requires precise and effective intervention.

At our Vienna clinic, Linear Accelerator (Linac) radiotherapy delivers high-energy X-rays and accelerates electrons to precisely conform to tumour shapes and sizes. This advanced approach ensures cancer cells are effectively targeted while preserving healthy tissue.

To find out more about the treatments we provide, get in touch with the Amethyst Radiotherapy team today.

Amethyst Radiotherapy UK Appoints Sasha Burns as New CEO.

Amethyst Group appoints Sasha Burns as CEO of UK Operations

/in , ,

Amethyst Group is pleased to welcome Sasha Burns as the new Chief Executive Officer (CEO) of UK Operations. With a strong background in healthcare leadership, strategic growth, and operational excellence, Sasha will play a key role in advancing Amethyst’s radiotherapy services and expanding access to world-class cancer treatment.

Bringing over 20 years of experience across both the NHS and independent sector, Sasha has a proven track record in transformational healthcare leadership. She previously held senior leadership roles at Alliance Medical, where she served as Chief Commercial and Operations Officer, and Nuffield Health, where she oversaw a network of hospitals and well-being centres. Her expertise spans business transformation, patient care innovation, and operational strategy.

With a background as a radiographer and an MBA from Henley Business School, Sasha combines clinical insight with strategic leadership, making her well-positioned to enhance Amethyst Group’s commitment to pioneering radiotherapy services.

“I am excited to join Amethyst Group and contribute to its mission of delivering innovative, high-quality radiotherapy care. As demand for advanced cancer treatments grows, I look forward to supporting the UK operations in expanding access and driving excellence,” said Sasha Burns.

Amethyst Group continues to strengthen its clinical expertise, patient-focused care, and cutting-edge radiotherapy technology across its European network. Sasha’s appointment reflects our ongoing commitment to innovation, growth, and leadership in oncology care.

CEO_Stephane Carre_Amethyst Healthcare Group

Stéphane Carré, CEO of Amethyst Healthcare, in The CEO Magazine

/in

We are delighted to announce that Stéphane Carré, CEO of Amethyst Healthcare Group, was recently featured in The CEO Magazine. In this exclusive interview, Stéphane shared his vision for advancing cancer care across Europe, highlighting the innovative solutions, strategic partnerships, and patient-first approach that define Amethyst Healthcare’s mission.

 

 

Prioritising Patient-Centred Care

A cancer diagnosis is life-changing, and Amethyst Healthcare aims to provide clarity, compassion, and confidence during this challenging journey. By integrating advanced radiotherapy as the core of our treatment approach, we focus on improving outcomes while minimising side effects.

As Stéphane Carré explained, radiotherapy remains one of the safest and most cost-effective cancer treatments available today. Its precision and adaptability make it suitable for a wide range of patients and conditions, ensuring we deliver care tailored to individual needs.

Building Strong Partnerships for Growth

Collaboration is at the heart of Amethyst Healthcare’s success. By partnering with public healthcare systems, we enhance access to state-of-the-art facilities while supporting existing medical infrastructure. This approach has enabled us to expand our services from Romania to six countries, including the UK, France, Italy, Austria, and Poland. Plans are already underway to enter a seventh European market, furthering our commitment to providing high-quality care.

Innovating for a Better Tomorrow

At Amethyst, we’re constantly looking to the future. From developing mobile apps to provide patients with personalised treatment data to streamlining diagnosis and therapy pathways, innovation drives everything we do. Stéphane Carré emphasised that creating an environment of trust and support for patients and their families is critical to achieving the best outcomes.

A Vision for the Future

Looking ahead, Amethyst Healthcare is focused on both expanding its current facilities and acquiring new ones to broaden its reach. This twofold growth strategy ensures we can serve more patients while continuing to provide timely, accessible, and effective cancer care.

Stéphane Carré summed it up best: “When patients feel supported and cared for, their outcomes improve. That’s the foundation of everything we do at Amethyst Healthcare.”

 

Read the full interview with Stéphane Carré in The CEO Magazine for more insights into Amethyst Healthcare Group’s inspiring journey.